# A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma

> **NCT00636311** · PHASE2 · COMPLETED · sponsor: **Istituto Clinico Humanitas** · enrollment: 13 (actual)

## Conditions studied

- Hodgkin Disease

## Interventions

- **DRUG:** Ifosfamide, Gemcitabine, Vinorelbine
- **DRUG:** Bortezomib + IGEV

## Key facts

- **NCT ID:** NCT00636311
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-04
- **Final completion:** 2010-02
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2010-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636311, "A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00636311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*